๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› UK
Clinical trial register · United Kingdom · industry-sponsored

Industry-sponsored studies with a UK investigative site

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors โ€” the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice โ€” all 2847 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 22 Sep 2026, 03:15 UTC
2847
Studies in scope
industry-sponsored, all four open statuses
1382
Recruiting now
open to new participants
542
Lead sponsors
across recruiting studies
Top sites
London 2004 Manchester 672 Birmingham 470 Glasgow 437 Cambridge 416
Narrow the register
Recruitment status
Phase
Lead sponsor
AstraZeneca195 Merck Sharp & Dohme LLC116 Hoffmann-La Roche105 Novartis Pharmaceuticals97 Janssen Research & Development, LLC93
Site city
London2004 Manchester672 Birmingham470 Glasgow437 Cambridge416
All 426 cities
Target enrolment
to
2847 of 2847 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Recruiting
To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva
NCT05090891Fibrodysplasia Ossificans Progressiva (FOP)
Incyte Corporation
Phase 2
98
Stanmore
2022-05-05
Active, closed
HM15136 (Efpegerglucagon) Treatment for 8 Weeks in Subjects Aged โ‰ฅ2 Years With Congenital Hyperinsulinism (CHI)
NCT04732416Congenital Hyperinsulinism
Hanmi Pharmaceutical Company Limited
Phase 2
17
London, Manchester
2022-05-05
Active, closed
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
NCT05269004Multiple Sclerosis
Hoffmann-La Roche
Phase 3
1,300
Nottingham, Exeter, Liverpool, London, Newcastle, Swansea
2022-05-03
Active, closed
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent ฮฒ-Thalassemia (TDT)
NCT05356195Beta-Thalassemia, Thalassemia, Genetic Diseases, Inborn, Hematologic Diseases
Vertex Pharmaceuticals Incorporated
Phase 3
16
London
2022-05-03
Active, closed
A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease
NCT05280548Fabry Disease
Sanofi
Phase 3
104
London
2022-05-03
Recruiting
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
NCT04879329Urothelial Carcinoma
Seagen, a wholly owned subsidiary of Pfizer
Phase 2
372
Glasgow, Cambridge, London, Manchester, Merseyside
2022-05-03
Active, closed
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)
NCT05329649Sickle Cell Disease, Hydroxyurea Failure, Hydroxyurea Intolerance, Hemoglobinopathies
Vertex Pharmaceuticals Incorporated
Phase 3
13
London
2022-05-02
Active, closed
Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.
NCT05270044Melanoma
Pierre Fabre Medicament
Phase 3
815
Preston, Newcastle upon Tyne
2022-05-02
Active, closed
Childrens Real Food Tolerance Study
NCT05269992Malnutrition, Child
Nutricia UK Ltd
Not applicable
60
Bristol
2022-05-01
Recruiting
A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Thalamotomy for the Treatment of Medication-Refractory Tremor Dominant Idiopathic Parkinson's Disease
NCT04991831Tremor Associated With Tremor Dominant Parkinson's Disease
InSightec
Observational
50
Dundee
2022-04-28
Active, closed
Evolutโ„ข EXPAND TAVR II Pivotal Trial
NCT05149755Moderate Aortic Valve Stenosis
Medtronic Cardiovascular
Not applicable
650
London
2022-04-27
Recruiting
First in Human Study of T3P-Y058-739 (T3P)
NCT05120596Advanced Solid Tumor
T3 Pharmaceuticals AG
Phase 1/2
100
Glasgow, Leeds, London, Southampton
2022-04-26
By invitation
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab
NCT05303532Cancer
AstraZeneca
Phase 3
214
London, Sheffield
2022-04-19
Active, closed
Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3
NCT05222906Gaucher's Disease Type III
Sanofi
Phase 3
43
London
2022-04-18
Recruiting
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
NCT05208047Advanced Gastrointestinal Stromal Tumors, Metastatic Cancer
Cogent Biosciences, Inc.
Phase 3
482
Cambridge, Glasgow, London, Manchester, Sheffield
2022-04-14
Active, closed
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
NCT05288166Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs
Eli Lilly and Company
Phase 3
925
Blackburn, Colchester, London
2022-04-14
Recruiting
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
NCT05131022Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL)
Nurix Therapeutics, Inc.
Phase 1
572
Manchester, Glasgow, Leeds, Liverpool, London, Oxford, Plymouth, Southampton
2022-04-13
Active, closed
CONVERGE Post-Approval Study (PAS)
NCT05393180Chronic Atrial Fibrillation
AtriCure, Inc.
Not applicable
53
London
2022-04-13
Recruiting
OSPREY is a Post-market, Global, Multicentre, Observational, Prospective Registry.
NCT04493632Pancreatic Neoplasm, Digestive System Neoplasm, Neoplasms by Site, Neoplasms
OncoSil Medical Limited
Observational
500
London
2022-04-12
Active, closed
Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients
NCT05074810Non Small Cell Lung Cancer, KRAS Activating Mutation
Verastem, Inc.
Phase 1/2
153
Leicester, London, Sutton
2022-04-12
Recruiting
Zimmerยฎ Natural Nailยฎ (ZNN) Bactiguard Tibia Post-Market Clinical Follow-up Study
NCT05022485Tibial Fractures, Fracture Infection
Zimmer Biomet
Observational
500
Edinburgh, Leeds, London
2022-04-11
Recruiting
Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Healthy Male and Female Subjects and Safety, Tolerability, Pharmacokinetics, and Pilot Efficacy Biomarkers in Subjects With Cold Agglutinin Disease
NCT05318534First in Man Study to Evaluate Initial Safety
Gliknik Inc.
Phase 1
70
Leeds
2022-04-08
Recruiting
Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer
NCT05329532Triple Negative Breast Cancer, Renal Cell Cancer, High Grade Ovarian Serous Adenocarcinoma, Squamous Cell Carcinoma of the Head and Neck
Scancell Ltd
Phase 1/2
168
Brighton, Cardiff, Edinburgh, Guildford, London, Manchester, Nottingham, Preston
2022-04-07
By invitation
Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)
NCT05248659Immunoglobulin A Nephropathy
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 2/3
600
Leicester, London
2022-04-05
Active, closed
Gekoโ„ข Cross Therapy Registry - Wound
NCT05007301Wound, Venous Leg Ulcer, Diabetic Foot Ulcer, Arterial Leg Ulcer
Firstkind Ltd
Observational
2,500
London, Norwich
2022-04-04
Active, closed
A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera
NCT05210790Polycythemia Vera
Protagonist Therapeutics, Inc.
Phase 3
293
Uxbridge, Barnet, Boston, Harrow, London, Oxford
2022-04-01
Active, closed
Precise Procedural and PCI Plan (P4)
NCT05253677Coronary Artery Disease
CoreAalst BV
Not applicable
1,090
Poole, Clydebank, Liverpool, London, Newcastle
2022-04-01
Active, closed
Olorofim Aspergillus Infection Study
NCT05101187Invasive Aspergillosis
F2G Biotech GmbH
Phase 3
225
Cardiff, London
2022-03-31
Recruiting
Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease
NCT05312879Proteinuric Kidney Disease
Vertex Pharmaceuticals Incorporated
Phase 2/3
466
Basildon, Bellshill, Birmingham, Carshalton, Leicester, London, Manchester, Nottingham
2022-03-30
Active, closed
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
NCT05270668Diffuse Cutaneous Systemic Sclerosis, Interstitial Lung Disease
Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2
154
London, Leeds
2022-03-29
Active, closed
A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria
NCT05196035Chronic Kidney Disease, Proteinuria
Bayer
Phase 3
219
London, Manchester, Nottingham, Glasgow
2022-03-28
Recruiting
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
NCT04895436Chronic Lymphocytic Leukemia (CLL)
AbbVie
Phase 2
75
Blackpool, Norwich, Leeds
2022-03-28
Recruiting
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT04928846Non Small Cell Lung Cancer
AbbVie
Phase 3
768
London, Nottingham, Birmingham, Manchester
2022-03-25
Recruiting
Clinical Assessment of Essential Remote Monitoring Functions in Pacemakers
NCT05165095Bradycardia, Remote Monitoring
MicroPort CRM
Observational
206
Basildon, London, Westcliff-on-Sea
2022-03-25
Active, closed
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
NCT05317416Multiple Myeloma
Pfizer
Phase 3
854
Cambridge, Birmingham, Belfast, Glasgow, Reading, Wolverhampton
2022-03-25
Active, closed
Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT05348577Prostate Cancer
AstraZeneca
Phase 3
1,035
Edinburgh, Glasgow, Guildford, Hackensack, London, Manchester, Southampton, Sutton
2022-03-25
Active, closed
A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors
NCT05135559Haemophilia A and B With and Without Inhibitors
Novo Nordisk A/S
Phase 3
153
Birmingham, Bristol, London
2022-03-24
Active, closed
Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)
NCT05224141Small Cell Lung Carcinoma
Merck Sharp & Dohme LLC
Phase 3
460
Manchester, Northwood, Birmingham
2022-03-24
Active, closed
Remote Optimization, Adjustment and Measurement for Deep Brain Stimulation
NCT05269862Parkinson Disease
Abbott Medical Devices
Not applicable
100
Glasgow
2022-03-24
Active, closed
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
NCT05277051Neoplasms
GlaxoSmithKline
Phase 1
152
Manchester, Sutton
2022-03-22
Recruiting
Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis
NCT04804553Active Juvenile Psoriatic Arthritis
Amgen
Phase 3
60
Birmingham, Liverpool, Nottingham, Oxford
2022-03-17
Active, closed
Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)
NCT05248646Immunoglobulin A Nephropathy
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
530
Cambridge, Gloucester, Leicester, London, Salford, Swansea
2022-03-15
Active, closed
A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
NCT05239728Carcinoma, Renal Cell
Merck Sharp & Dohme LLC
Phase 3
1,800
London, Nottingham, Glasgow, Manchester, Swansea
2022-03-15
Active, closed
LEVANTIS-0093A: GAGomes for Multi-Cancer Early Detection in High-Risk Adults (LEV93A)
NCT05295017Cancer
Elypta
Observational
1,235
Leeds
2022-03-14
Active, closed
A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants โ‰ฅ16 Years of Age With Fabry Disease
NCT05206773Fabry Disease
Sanofi
Phase 3
122
Cambridge, London, Salford
2022-03-11
Recruiting
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
NCT05315700Solid Tumors
ORIC Pharmaceuticals
Phase 1/2
350
Manchester
2022-03-10
Active, closed
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
NCT05100862Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma
BeOne Medicines
Phase 3
799
Glasgow, Greater Manchester, Huddersfield, Inverness, Leeds, London, Plymouth, Southampton
2022-03-10
Active, closed
Long-Term Follow-Up (LTFU) for Gene Therapy of Leukocyte Adhesion Deficiency-I (LAD-I)
NCT06282432Leukocyte Adhesion Deficiency
Rocket Pharmaceuticals Inc.
Observational
9
London
2022-03-09
Active, closed
A Phase 3 Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder.
NCT05064878CDKL5 Deficiency Disorder, Generalized Tonic Clonic Seizure, Epileptic Spasm, Refractory Seizures
Zogenix, Inc.
Phase 3
87
Bristol, London, Manchester, Sheffield
2022-03-08
Recruiting
An Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3705 in Participants Previously Enrolled in Other Clinical Studies of mRNA-3705
NCT05295433Methylmalonic Acidemia
ModernaTX, Inc.
Phase 1/2
56
Birmingham, Manchester
2022-03-08
Recruiting
EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease
NCT05261139COVID-19
Pfizer
Phase 3
160
London
2022-03-07
Active, closed
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
NCT05132582HER2 Positive Breast Cancer
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
654
London, Sutton, Manchester
2022-03-07
Recruiting
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
NCT05091424Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Hoffmann-La Roche
Phase 1
332
Manchester, Oxford
2022-03-07
Active, closed
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
NCT05215340Metastatic Non Small Cell Lung Cancer
Daiichi Sankyo
Phase 3
740
Birmingham, Nottingham
2022-03-04
Recruiting
Follow-up Study to Monitor the Efficacy and Safety of the Occlutechยฎ mVSD Cases
NCT05329350Muscular Ventricular Septal Defect
Occlutech International AB
Observational
50
London
2022-03-03
Recruiting
Phase 2 Study to Assess the Safety, PK, and PD of Sonefpeglutide (HM15912) in SBS-IF Subjects
NCT04775706Short Bowel Syndrome
Hanmi Pharmaceutical Company Limited
Phase 2
18
Salford, London
2022-03-03
Active, closed
A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis
NCT05250973Amyloidosis
Janssen Research & Development, LLC
Phase 2
151
Leicester, London
2022-03-01
Recruiting
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
NCT04988555Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, Multiple Myeloma, Myelodysplastic Syndromes
Sumitomo Pharma America, Inc.
Phase 1/2
606
Birmingham, Bristol, Edinburgh, London, Manchester, Oxford, Stoke-on-Trent, Sutton
2022-02-28
Active, closed
A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection
NCT05120349Non-Small Cell Lung Cancer
AstraZeneca
Phase 3
390
Birmingham, Blackpool, London, Nottingham, Wythenshawe
2022-02-21
Active, closed
Setrusumab vs Placebo for Osteogenesis Imperfecta
NCT05125809Osteogenesis Imperfecta
Ultragenyx Pharmaceutical Inc
Phase 2/3
183
Manchester, Sheffield
2022-02-21
Active, closed
Clinical Impact of the IBox As an Early Intervention TooL
NCT05112315Kidney Diseases, Kidney Disease, Chronic, Kidney Transplant Rejection, Kidney Transplant; Complications
Predict4Health
Not applicable
507
Birmingham, Leeds, London, Oxford
2022-02-18
Active, closed
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
NCT05211895Non-Small Cell Lung Cancer
AstraZeneca
Phase 3
791
Birmingham, Brighton, Cardiff, Cheltenham, Edinburgh, High Heaton/Newcastle Upon Tyn, Leeds, London
2022-02-18
Recruiting
Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant
NCT05027906Prevention of Rejection in Kidney Transplant
Eledon Pharmaceuticals
Phase 1/2
48
Liverpool, Oxford
2022-02-18
Active, closed
A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration
NCT05230537Age-Related Macular Degeneration
Novartis Pharmaceuticals
Phase 2
170
London, Southampton
2022-02-17
Active, closed
A Phase III Study of JR-141 in Patients With Mucopolysaccharidosis II (STARLIGHT)
NCT04573023Mucopolysaccharidosis II
JCR Pharmaceuticals Co., Ltd.
Phase 3
86
London
2022-02-14
Active, closed
A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)
NCT05031780Sickle Cell Disease
Agios Pharmaceuticals, Inc.
Phase 2/3
286
London, Cambridge, Manchester
2022-02-11
Recruiting
A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
NCT04779320Crohn's Disease (CD)
Takeda
Phase 3
120
London, Cardiff, Birmingham, Manchester
2022-02-10
Active, closed
A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
NCT05221840Non-Small Cell Lung Cancer
AstraZeneca
Phase 3
1,051
Belfast, Bristol, Dundee, Edinburgh, London, Middlesbrough, Poole, Torquay
2022-02-07
Active, closed
Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease
NCT05202509Atherosclerotic Cardiovascular Disease
NewAmsterdam Pharma
Phase 3
9,541
Penzance, Belfast, Birmingham, Blackpool, Cardiff, Durham, Enfield, Fowey
2022-02-07
Recruiting
A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD
NCT05231785Early-Onset Alzheimer Disease
Alnylam Pharmaceuticals
Phase 1
60
Huntley Street, Sheffield
2022-02-04
Active, closed
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
NCT05173987Endometrial Neoplasms
Merck Sharp & Dohme LLC
Phase 3
280
Manchester, Glasgow, London
2022-02-03
By invitation
A Study to Test the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
NCT05076617Stereotypical Prolonged Seizures
UCB Biopharma SRL
Phase 3
300
Birmingham, Glasgow, London, Oxford, Salford
2022-02-03
Recruiting
Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
NCT05070845Primary Immune Thrombocytopenia
Pfizer
Phase 2
91
Cambridge, Plymouth, Truro, London
2022-02-02
Active, closed
A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOGAD)
NCT05063162Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD)
UCB Biopharma SRL
Phase 3
113
Liverpool, Oxford
2022-02-02
Active, closed
A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)
NCT05094336Advanced MTAP-null Solid Tumors
Amgen
Phase 1/2
329
London, Sutton
2022-02-01
By invitation
Long-Term Follow-up: Phase I/II Clinical Study to Evaluate the Safety and Efficacy of the Infusion of RP-L102
NCT07527975Fanconi Anemia
Rocket Pharmaceuticals Inc.
Observational
14
London
2022-02-01
Active, closed
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN)
NCT05262023Frontotemporal Dementia
Denali Therapeutics Inc.
Phase 1/2
85
Merthyr Tydfil
2022-02-01
Active, closed
West Hertfordshire Inflammatory Bowel Disease Technology Study
NCT05000242Inflammatory Bowel Diseases
Perspectum
Observational
200
Watford
2022-01-31
Active, closed
Gene Therapy Study for Children With CLN5 Batten Disease
NCT05228145Neuronal Ceroid Lipofuscinosis CLN5
Neurogene Inc.
Phase 1/2
6
London
2022-01-31
By invitation
Post Market Clinical Follow-Up Study for EVOLUTIONยฎ NitrXโ„ข Keeled Tibia and EVOLUTIONยฎ NitrXโ„ข CS/CR Femur With Cruciate Sacrificing Insert
NCT04816773Joint Diseases, Osteoarthritis, Arthritis Knee, Avascular Necrosis
MicroPort Orthopedics Inc.
Observational
150
Grantham
2022-01-27
Active, closed
Safety and Clinical Activity of QEL-001 in A2-mismatch Liver Transplant Patients
NCT05234190Rejection; Transplant, Liver, Liver Failure, Liver Diseases
Quell Therapeutics Limited
Phase 1/2
33
Birmingham, Cambridge, London
2022-01-21
Active, closed
ADH1 and ADH2 Disease Monitoring Study (DMS)
NCT05227287Autosomal Dominant Hypocalcemia
Calcilytix Therapeutics, Inc., a BridgeBio company
Observational
95
Manchester
2022-01-20
Active, closed
Rhenium-Skin Cancer Therapy (SCT) for the Treatment of Non-Melanoma Skin Cancer.
NCT05135052Non-melanoma Skin Cancer
OncoBeta Therapeutics
Not applicable
210
London
2022-01-17
Active, closed
A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
NCT05002127Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma
ALX Oncology Inc.
Phase 2/3
127
London
2022-01-15
Active, closed
LVISโ„ข Evoโ„ข and HydroCoilยฎ Embolic System for Intracranial Aneurysm Treatment
NCT04999423Intracranial Aneurysm
Microvention-Terumo, Inc.
Observational
206
Edinburgh, Liverpool, London
2022-01-14
Recruiting
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
NCT05139017DLBCL, Diffuse Large B-Cell Lymphoma
Merck Sharp & Dohme LLC
Phase 2/3
290
Aberdeen, Truro, London-Camden
2022-01-14
Recruiting
The "Global Paradise System" Registry
NCT05027685Hypertension
ReCor Medical, Inc.
Observational
3,000
Bournemouth, Canterbury, Cardiff, Dudley, Glasgow, Hull, London, Newcastle
2022-01-13
Active, closed
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
NCT05407636AMD, nAMD, Wet Age-related Macular Degeneration, wAMD
AbbVie
Phase 3
735
Aylesbury, London, Gloucester, Southampton, Oxford, Leeds, Bradford, Bristol
2022-01-13
Active, closed
Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis
NCT05201638Multiple Sclerosis, Relapsing-Remitting
Immunic AG
Phase 3
1,100
Sheffield
2022-01-12
Active, closed
An Efficacy and Safety Study of Basimglurant (NOE-101) in Patients With Trigeminal Neuralgia.
NCT05217628Trigeminal Neuralgia
Noema Pharma AG
Phase 2/3
166
London
2022-01-11
Recruiting
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
NCT05118789Locally Advanced Solid Tumor, Metastatic Solid Tumor
Nuvalent Inc.
Phase 1/2
359
London, Manchester
2022-01-04
Recruiting
Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II
NCT05102019Refractory Angina
Shockwave Medical, Inc.
Not applicable
380
Basildon, Birmingham, Bristol, Cambridge, Dorchester, Kettering, Leicester, Liverpool
2022-01-04
Active, closed
HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome
NCT05127226Angelman Syndrome
Ionis Pharmaceuticals, Inc.
Phase 1/2
71
Oxford
2021-12-22
Active, closed
Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE
NCT04919226Neuroendocrine Tumors
ITM Solucin GmbH
Phase 3
259
London
2021-12-21
Active, closed
Effectiveness of the SpaceOAR Vue System in Subjects With Prostate Cancer
NCT04905069Prostate Cancer
Boston Scientific Corporation
Not applicable
500
Guildford, Cardiff, Belfast, Bristol, London, Norwich, Plymouth
2021-12-21
Recruiting
Post Marketing Clinical Follow Up Study to Evaluate Efficacy and Safety of the Occlutech PDA Occluder in Patients With Patent Ductus Arteriosus Defects
NCT05264753Patent Ductus Arteriosus
Occlutech International AB
Observational
255
London
2021-12-20
Active, closed
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT04819100Carcinoma, Non-Small-Cell Lung
Eli Lilly and Company
Phase 3
152
London, Nottingham, Wolverhampton
2021-12-20
Active, closed
A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (ฮฑ- or ฮฒ-NTDT)
NCT04770753Non-Transfusion-dependent Alpha-Thalassemia, Non-Transfusion-dependent Beta-Thalassemia
Agios Pharmaceuticals, Inc.
Phase 3
194
Cambridge, Manchester, London
2021-12-20
Active, closed
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
NCT05097287Asthma
Sanofi
Phase 4
1,339
Cambridge, Oxford, Bradford, Liverpool, Newcastle upon Tyne, Wakefield
2021-12-16
Recruiting
A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis
NCT05037760Myelofibrosis
Takeda
Phase 2
135
Boston, Leeds, London
2021-12-16
Rows per page Showing 2001–2100 of 2847
Previous 19 20 21 22 23 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site. Derived from ClinicalTrials.gov. Retrieved 22 September 2026. https://priyalifescience.com/clinical-trials-uk?page=21

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.